Skip to content

Regulatory Considerations DMEG Update

Date: December 4, 2025

With mixed feelings, we share that Silvia Pérez Torres, current chair of the ACDM Regulatory Considerations DMEG, will step down after five years of dedicated service. As a founding member, Silvia helped launch the DMEG in February 2021.  Silvia set a clear vision, built a high‑performing, inclusive team across the world, and cultivating a culture of collaboration and excellence across the group and the wider ACDM community.

Under Silvia’s leadership, the DMEG coordinated consensus feedback to regulators on key publications from ICHEMA, and FDA, and translated evolving requirements—such as ICH E6(R3), ICH E8(R1), FDA Digital Health Technologies, Data Monitoring Committees, and the Q&A on Electronic Systems, Records, and Signatures—into practical guidance and best practices for data management. She also helped connect the community through initiatives like the Hot Topic session on ICH E6(R3) and the ACDM publication, “Getting Started with Audit Trail Review in Clinical Trial Data.”

Thank you, Silvia, for your leadership, team building, and collaborative spirit—your impact on our community is lasting.

Looking ahead, Linda Shostak, a current DMEG member, will assume the chair role in January 2026. Silvia and Linda will work closely to ensure a smooth transition and continued momentum into 2026. Please join us in thanking Silvia for her outstanding service and in welcoming Linda to her new leadership role.

If you are interested in learning more about the Regulatory considerations DMEG or are interested in joining the group you can locate us on the ACDM website here.

 


 

Explore More News

ACDM Regulatory Considerations DMEG Update: ICH E6 (R3) GCP Final Publication Released

The final publication of ICH E6 (R3) Good Clinical Practice (GCP) General Principles and . . .

Read More

ICH E6(R3) Guideline reaches Step 4 of the ICH Process

ICH E6(R3) reaches Step 4 of the ICH Process on 6th January 2025. The guideline . . .

Read More

U.S. Food & Drug Administration: Draft Guidance for Industry and Other Interested Parties

The U.S. Food and Drug Administration has issued its first guidance on the use of . . .

Read More

ACDM DMEG News: Regulatory Updates and Forthcoming Challenges for 2025

As 2024 draws to a close, the Regulatory Considerations Data Management Expert Group . . .

Read More

Audit Trail Review DMEG Update – New Guide

The Audit Trail Review (ATR) DMEG has been hard at work putting the finishing touches on a . . .

Read More

Risk Based Quality Management DMEG Update – Recent Discussions

This year our focus has switched away from generalised RBQM to applying risk-based . . .

Read More

Regulatory Considerations DMEG Update – September 2024

The Regulatory Considerations DMEG are waiting for the release of ICH GCP E6 (R3) Annex 1 . . .

Read More

Digital Data Flow (DDF) integration through the lens of electronic Patient-Reported Outcomes (ePRO)

This article has been submitted by Leeni Joshua of ICON plc Introduction: Digital Data . . .

Read More

Guidance for Industry: Conducting Clinical Trials With Decentralized Elements

The Conducting Clinical Trials With Decentralized Elements final guidance has now been . . .

Read More

Welcome FGK Clinical Research as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome FGK Clinical . . .

Read More

Welcome LINK Medical as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome LINK Medical as . . .

Read More

Welcome Zilla Clinicals as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome Zilla Clinicals . . .

Read More